Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment

Stock Track

05/27

GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.

The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.

Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1196637242"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196637242\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196637242?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196637242","market":"sg","top_or_hot":-1,"title":"Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment","media":"Stock Track","content":"<p>GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.</p><p>The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.</p><p>Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-27 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.</p><p>The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.</p><p>Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1196637242","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196637242","pubTimestamp":1779846865,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.The surge follows news that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"个股追踪|金斯瑞生物盘中大涨5.57%受ASCO数据公布及估值情绪影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}